Evidence map›Paper›PMID 38546932›Full record

ArticleActa neurologica Belgica2024

Evaluation of the relationship between FDG-PET hypometabolism and retinal layer thickness in patients with Alzheimer's disease.

Demet Duman Sastim, Gulcin Elboga, Umut Elboga, Kivanc Gungor

Abstract read
PubMed Publisher
In one paragraph

Article in Acta neurologica Belgica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Demet Duman SastimDepartment of Psychiatry, Tunceli State Hospital, Merkez, 62000, Merkez/Tunceli, Turkey. dr.demet_62@hotmail.com.ORCID http://orcid.org/0000-0002-1067-3802
Gulcin ElbogaFaculty of Medicine, Department of Psychiatry, Gaziantep University, Gaziantep, Turkey.
Umut ElbogaFaculty of Medicine, Department of Nuclear Medicine, Gaziantep University, Gaziantep, Turkey.
Kivanc GungorFaculty of Medicine, Department of Ophthalmology, Gaziantep University, Gaziantep, Turkey.
Gaziantep University · TRMunzur University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We aimed to investigate the diagnostic value of Optical coherence tomography (OCT) in Alzheimer's disease (AD) and to assess the correlation between OCT and fluorodeoxyglucose (FDG)-positron emission tomography (PET) which shows high diagnostic agreement with findings from postmortem histopathology-the gold standard method. Patients who were diagnosed with AD-related dementia were selected for the study. Patients with a mini mental test (MMT) score between 18 and 23 were included in the study (n = 31). Volunteers with MMT ≥ 28 and no cognitive impairment were included in the study as the control group (n = 31). OCT imaging was performed in the patient and control groups after detailed ophthalmological examinations including visual acuity and intraocular pressure measurements. Brain glucose metabolism measurement was performed using 18 F-FDG PET/computed tomography. When adjusted for age and sex, mean retinal nerve fiber layer thickness (RNFL) thickness showed a significant difference between groups and the RNFL thickness in the superior temporal and superior nasal quadrants in AD-related mild dementia group showed a significant difference (p < 0.05). Furthermore, only the RNFL thickness in the inferior nasal quadrant of the right eye showed a significant difference between the groups (p = 0.016). It is thought that OCT is a promising imaging method in the elderly population due to its low-cost, non-invasive and easily applicability, and therefore, it may contribute in the future as a tool in the periodic follow-up of patients diagnosed with AD.

Indexed as

Alzheimer DiseaseFluorodeoxyglucose F18Positron-Emission TomographyRetinaTomography, Optical CoherenceAgedAged, 80 and overFemaleHumansMaleMiddle AgedPositron Emission Tomography Computed TomographyRadiopharmaceuticalsFluorodeoxyglucose F18RadiopharmaceuticalsCognitive functionsDementiaPositron emission tomographyRetinal neurodegeneration

Identifiers

PMID38546932
OpenAlexW4393272060

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.